China SXT Pharmaceuticals (SXTC) announced that it has entered into a definitive agreement with a single investor for the purchase and sale of an aggregate of 66.67M Class A ordinary shares of the company at a purchase price of 15c per share in a registered direct offering. The aggregate gross proceeds to the company of this offering are expected to be approximately $10M. The transaction is expected to close on or about January 12, subject to the satisfaction of customary closing conditions. Univest Securities is acting as the sole placement agent.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTC:
- Why Is Penny Stock China SXT (SXTC) Up Almost 200% Today?
- Midday Fly By: Defense stocks surge on Trump budget request
- China SXT announces launch of Strategic AI Insights Initiative
- China SXT Pharmaceuticals Files First-Half 2025 Financial Results on Form 6-K
- China SXT Pharmaceuticals files $600M mixed securities shelf